April 28th, 7 pm - 9 pm ET
Overview
The treatment of relapsed/refractory multiple myeloma (R/R MM) has become challenging owing to the variety of novel agents and combinations available for patients with early relapse as well as those in later lines of therapy. The selection and sequencing of therapy, in addition to adverse event management, can be daunting given the diverse class of agents now approved, such as monoclonal antibodies, selective inhibitors of nuclear export, anti-BCMA antigens, and peptide-drug conjugates.
The Reflective Case-Based Oncology Collective™ combines a core curriculum developed by renowned experts in MM with real-world cases that challenge learners to reflect on the application of the evidence to their own clinical practice, bringing together physicians to collectively consider the ramifications for care of new approaches to treatment and clinical management of R/R MM.
Target Audience
This activity is directed toward medical oncologists and hematologist/oncologists who treat patients with multiple myeloma. Other oncology healthcare professionals including nurses and pharmacists who manage patients with multiple myeloma are invited to participate.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Explain the impact of risk stratification and treatment resistance on decision-making among patients with multiple myeloma in early relapse
- Examine efficacy and safety results from clinical trials conducted among patients with relapsed/refractory multiple myeloma in later lines of therapy
- Integrate treatment algorithms based on patient-, disease-, and treatment-factors to select optimal therapies for patients with relapsed/refractory multiple myeloma at different points in their disease journey
- Demonstrate ability to incorporate landmark and recent clinical trial evidence to practically manage patients with relapsed/refractory multiple myeloma
Ajai Chari, MD
Director, Clinical Research, Multiple Myeloma Program
Associate Medical Director, Tisch Cancer Institute Clinical Trials Office
Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine, Mt.
Sinai New York
Disclosures: Grant Research Support: Janssen Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Amgen, Inc., Pharmacyclics LLC, Seagen Inc., Takeda Oncology; Consultant: Janssen Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Amgen, Inc., Bristol Myers Squibb, Karyopharm Therapeutics, Sanofi Genzyme, Seagen Inc., Oncopeptides, Takeda Oncology, Antengene, GlaxoSmithKline, Secura Bio, Shattuck Labs.
Noa Biran, MD
Associate Professor of Medicine
Hackensack University School of Medicine
Multiple Myeloma Division
The John Theurer Cancer Center
Disclosures: Grant Research Support: Merck, Janssen, Karyopharm, Amgen, BMS; Consultant: Sanofie, AbbVie, BMS; Speaker’s Bureau: BMS, Janssen.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.